Prophylaxis of migraine headache.
Pringsheim
Tamara
T
Department of Clinical Neurosciences, University of Calgary, Calgary Headache Assessment and Management Program, Foothills Medical Centre, 1403-29th St. NW, Calgary AB T2N 2T9. tmprings@ucalgary.ca
Davenport
W Jeptha
WJ
Becker
Werner J
WJ
D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D003657:Decision Making; D005444:Flunarizine / Q000627:therapeutic use; D006801:Humans; D008881:Migraine Disorders / Q000175:diagnosis / Q000517:prevention & control*; D009465:Neuromuscular Agents / Q000627:therapeutic use; D008517:Phytotherapy; D010918:Pizotyline / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012017:Referral and Consultation; D014815:Vitamins / Q000627:therapeutic use
D000927:Anticonvulsants; D000928:Antidepressive Agents; D000959:Antihypertensive Agents; D009465:Neuromuscular Agents; D014815:Vitamins; D010918:Pizotyline; D019274:Botulinum Toxins, Type A; D005444:Flunarizine